Age-stratified outcome of genotype-guided dosing algorithm for acenocoumarol and phenprocoumon

BACKGROUND: Age seemed to affect the interaction between coumarins and genotype in the acenocoumarol and phenprocoumon arm of the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial. OBJECTIVES: To investigate the effect of genotype-guided dosing stratified by age and the potential factors causing a difference. PATIENTS/METHODS: Data from the acenocoumarol/phenprocoumon arm of the EU-PACT trial was used. The percentage of time below, above and in the therapeutic range (TTR) during the initial 12 weeks of therapy were compared between the genotype-guided group and the control group among younger (